A recent press release from Auspex Pharmaceuticals reported on an interim analysis from their ongoing ARC-HD trial that switching from tetrabenazine (Xenazine) to SD-109, resulted in equal control of chorea in Huntington's disease. SD-109 is a chemically modified form of tetrabenazine that allows for a lower dosing regimen. It is hoped that lower dosing of SD-109 will result in fewer side effects than the present form tetrabenazine.
For more than a decade, couples at risk for Huntington's disease have had the option
to conceive an unaffected child by utilizing the reproductive process of preimplantation
geneticdiagnosis (PGD). If PGD became common practice in HD, it could eliminate the majority of disease for the next generation. So if PGD has the potential to mostly "wipe out" HD for the next generation, why is it so rarely utilized?
Treatment Guidelines for Huntington's: Who needs them?
Posted by LaVonne Goodman M.D.
During my years as an internal medicine physician, I have used standard of care guidelines for my patients with conditions like diabetes and heart disease. Guidelines are developed by experts in each disease who
translate clinical trial evidence and/or expert experience into recommended care patterns
for use in medical offices or at the bedside. When followed, guidelines have been central to improving the
quality of care provided by all physicians whether they are specialists or